{"id":308,"date":"2026-04-11T17:15:24","date_gmt":"2026-04-11T17:15:24","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&p=308"},"modified":"2026-09-30T09:05:13","modified_gmt":"2026-09-30T09:05:13","slug":"luciolap-olaparib-150-mgx120-tablets","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/ar\/product\/luciolap-olaparib-150-mgx120-tablets\/","title":{"rendered":"LuciOlap"},"content":{"rendered":"

HIGHLIGHTS OF PRESCRIBING INFORMATION <\/strong><\/span><\/p>\n

These highlights do not include all the information needed to use LUCIOLAP safely and effectively. See full prescribing information for LUCIOLAP.<\/strong><\/span><\/p>\n

 <\/span><\/p>\n

INDICATIONS AND USAGE<\/strong><\/strong><\/span><\/p>\n

LUCIOLAP is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:<\/span><\/p>\n

Ovarian cancer<\/span><\/p>\n

 \u2022  for the maintenance treatment of adult patients with deleterious or suspected  deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for LUCIOLAP. <\/span><\/p>\n

 \u2022  in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy  and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either:<\/span><\/p>\n

 \u2022  a deleterious or suspected deleterious BRCA mutation, and\/or<\/span><\/p>\n

 \u2022  genomic instability.<\/span><\/p>\n

Select patients for therapy based on an FDA-approved companion diagnostic for LUCIOLAP.<\/span><\/p>\n

 \u2022  for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an  FDA-approved companion diagnostic for LUCIOLAP.<\/span><\/p>\n

Breast cancer<\/span><\/p>\n

 \u2022  for the adjuvant treatment of adult patients with deleterious or suspected  deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for LUCIOLAP.<\/span><\/p>\n

 \u2022  for the treatment of adult patients with deleterious or suspected deleterious  gBRCAm, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for LUCIOLAP. <\/span><\/p>\n

Pancreatic cancer<\/span><\/p>\n

 \u2022  for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for LUCIOLAP. <\/span><\/p>\n

Prostate cancer<\/span><\/p>\n

 \u2022  for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for LUCIOLAP. <\/span><\/p>\n

 \u2022  in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for LUCIOLAP.<\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE AND ADMINISTRATION<\/strong><\/strong><\/span><\/p>\n

\u2022  Recommended dosage is 300 mg taken orally twice daily with or without food. See Full Prescribing Information for the recommended duration. <\/strong><\/span><\/p>\n

\u2022  Patients receiving LUCIOLAP for mCRPC should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. <\/span><\/p>\n

\u2022  For moderate renal impairment (CLcr 31-50 mL\/min), reduce LUCIOLAP dosage to  200 mg orally twice daily.<\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE FORMS AND STRENGTHS <\/strong><\/strong><\/span><\/p>\n

Tablets: 150 mg\u00d7120 tablets<\/span><\/p>\n

 <\/span><\/p>\n

CONTRAINDICATIONS <\/strong><\/strong><\/span><\/p>\n

None.<\/span><\/p>\n

 <\/span><\/p>\n

WARNINGS AND PRECAUTIONS <\/strong><\/strong><\/span><\/p>\n

\u2022 Myelodysplastic Syndrome\/Acute Myeloid Leukemia (MDS\/AML): Occurred in approximately 1.2% of patients with various BRCAm, gBRCAm, HRR gene-mutated or HRD-positive cancers exposed to LUCIOLAP and the majority of events had a fatal outcome. Monitor patients for hematological toxicity at baseline and monthly thereafter. Discontinue if MDS\/AML is confirmed. <\/span><\/p>\n

\u2022 Pneumonitis: Occurred in 0.8% of patients exposed to LUCIOLAP, and some cases were fatal. Interrupt treatment if pneumonitis is suspected. Discontinue if pneumonitis is confirmed.<\/span><\/p>\n

\u2022 Venous thromboembolism (VTE), including severe or fatal pulmonary embolism (PE), occurred in patients treated with LUCIOLAP. VTE occurred in 8% of patients with mCRPC. Monitor patients for signs and symptoms of VTE and PE and treat as medically appropriate. <\/span><\/p>\n

\u2022 Embryo-Fetal Toxicity: Can cause fetal harm. Advise of the potential risk to a fetus and to use effective contraception. <\/span><\/p>\n

 <\/span><\/p>\n

ADVERSE REACTIONS <\/strong><\/strong><\/span><\/p>\n

Most common adverse reactions (\u226510%) in clinical trials:<\/span><\/p>\n

\u2022 as a single agent were nausea, fatigue (including asthenia), anemia, vomiting, diarrhea, decreased appetite, headache, dysgeusia, cough, neutropenia, dyspnea, dizziness, dyspepsia, leukopenia, and thrombocytopenia. <\/span><\/p>\n

\u2022 in combination with bevacizumab were nausea, fatigue (including asthenia), anemia, lymphopenia, vomiting, diarrhea, neutropenia, leukopenia, urinary tract infection, and headache. <\/span><\/p>\n

\u2022 in combination with abiraterone and prednisone or prednisolone were anemia, fatigue, nausea, diarrhea, decreased appetite, lymphopenia, dizziness, and abdominal pain. <\/span><\/p>\n

 <\/span><\/p>\n

DRUG INTERACTIONS <\/strong><\/strong><\/span><\/p>\n

\u2022  Strong or moderate CYP3A inhibitors: Avoid concomitant use. If concomitant use cannot be avoided, reduce LUCIOLAP dosage.<\/span><\/p>\n

\u2022  Strong or moderate CYP3A inducers: Avoid concomitant use.<\/span><\/p>\n

 <\/span><\/p>\n

USE IN SPECIFIC POPULATIONS <\/strong><\/strong><\/span><\/p>\n

Lactation: Advise women not to breastfeed.<\/span><\/p>\n

 <\/span><\/p>\n

Storage <\/strong><\/strong><\/span><\/p>\n

Store at 20\u2103 to 25\u2103 (68\u2109 to 77\u2109), excursions permitted between 15\u2103 and 30\u2103 (59\u2109 and 86\u2109) [see USP Controlled Room Temperature]. Protect from moisture. <\/span><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

LuciOlap contains olaparib and is supplied as 150 mg tablets in a pack of 120. Please review the full product information with your prescriber. A valid prescription and identity verification are required before ordering.<\/p>","protected":false},"featured_media":1979,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[46],"product_tag":[],"class_list":["post-308","product","type-product","status-publish","has-post-thumbnail","product_cat-ovarian-cancer","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product\/308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/comments?post=308"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/media\/1979"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/media?parent=308"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product_brand?post=308"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product_cat?post=308"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product_tag?post=308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}